Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2013

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2013

Jun 2013 Global Markets Direct Lymphoma73 Pages Price :
$ 2000

Global Markets Directs, Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H1 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL). 

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Anaplastic Large Cell Lymphoma (ALCL).
  • A review of the Anaplastic Large Cell Lymphoma (ALCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Anaplastic Large Cell Lymphoma (ALCL) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anaplastic Large Cell Lymphoma (ALCL) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) 8
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics under Development by Companies 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Products under Development by Companies 15
Companies Involved in Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Development 16
AstraZeneca PLC 16
Seattle Genetics, Inc. 17
Pfizer Inc. 18
Teva Pharmaceutical Industries Limited 19
Sareum Holdings plc 20
Xencor, Inc. 21
Korea Research Institute of Chemical Technology 22
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
CEP-28122 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
brentuximab vedotin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
XmAb-2513 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SGN-30 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CEP-37440 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Aurora Kinases + ALK Kinase Program - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AKR-302 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AZD-3463 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
KRA-0008 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AKR-303 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Drug Profile Updates 44
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics - Dormant Products 58
Anaplastic Large Cell Lymphoma (ALCL) Product Development Milestones 59
Featured News & Press Releases 59
Jun 01, 2013: Takeda Highlights Data From Phase I/II Clinical Trial Examining Use Of Adcetris in Pediatric Patients With Hodgkin Lymphoma Or Systemic Anaplastic Large Cell Lymphoma 59
May 14, 2013: Seattle Genetics Announces Adcetris Supplemental BLA Accepted For Filing By FDA 60
Mar 22, 2013: Takeda Submits New Drug Application For Brentuximab Vedotin In Japan 61
Mar 18, 2013: Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With Adcetris In Relapsed Hodgkin Lymphoma And Systemic ALCL 62
Feb 01, 2013: Seattle Geneticss Adcetris Obtains Canadian Approval For Treatment Of Hodgkin Lymphoma And Systemic Anaplastic Large Cell Lymphoma 63
Jan 24, 2013: Seattle Genetics And Millennium Initiate Global Phase III Clinical Trial Of Adcetris In Front-line CD30-Expressing Mature T-Cell Lymphoma 64
Dec 09, 2012: Seattle Genetics Highlights Adcetris Data In CD30-Positive Non-Hodgkin Lymphomas And Other Malignancies From Multiple Presentations At ASH Annual Meeting 65
Nov 05, 2012: Seattle Genetics To Present Data On Adcetris And Antibody-Drug Conjugates At American Society Of Hematology Annual Meeting 67
Oct 31, 2012: Takeda And Millennium Announce European Conditional Marketing Authorization For Adcetris 69
Oct 01, 2012: Millennium And Seattle Genetics Highlight Data From ADCETRIS Trial In Patients With Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma 70

Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Table


Number of Products Under Development for Anaplastic Large Cell Lymphoma (ALCL), H1 2013 8
Products under Development for Anaplastic Large Cell Lymphoma (ALCL) Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
AstraZeneca PLC, H1 2013 16
Seattle Genetics, Inc., H1 2013 17
Teva Pharmaceutical Industries Limited, H1 2013 19
Sareum Holdings plc, H1 2013 20
Xencor, Inc., H1 2013 21
Korea Research Institute of Chemical Technology, H1 2013 22
Assessment by Monotherapy Products, H1 2013 23
Assessment by Combination Products, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 28
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Drug Profile Updates 44
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Dormant Products 58

List of Chart


Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H1 2013 8
Products under Development for Anaplastic Large Cell Lymphoma (ALCL) Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 23
Assessment by Combination Products, H1 2013 24
Assessment by Route of Administration, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 26
Assessment by Molecule Type, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 28

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top